With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

Emraclidine was expected to be a blockbuster drug for AbbVie, and this development didn’t sit well with investors.

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials of its experimental schizophrenia ... % as fears about the AbbVie drug's ...

Pharmaceutical company AbbVie announced that an experimental schizophrenia drug that was key to its $8.7 billion acquisition ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

Truist analyst Srikripa Devarakonda notes that AbbVie (ABBV) announced negative trial results for emraclidine in dual Phase 2 schizophrenia ...

Shares of AbbVie plummeted Monday after the company said its schizophrenia drug Emraclidine missed key goals in a pair of trials.

AbbVie's emraclidine trials for schizophrenia fail, leading to stock decline, but analysts maintain confidence in the company ...

If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...